In our cohort, the VNPI – considered a useful prognostic marker for treatment decision making in DCIS – could potentially avoid overtreatment in 16% of the DCIS patients; using CD10, this figure reached 28.5%. The gene discussed is MME; the disease is ductal breast carcinoma in situ.